Kalvista Deferred Long Term Liab from 2010 to 2025
| KALV Stock | USD 12.34 0.27 2.24% |
Deferred Long Term Liabilities | First Reported 2010-12-31 | Previous Quarter 64.4 K | Current Value 61.2 K | Quarterly Volatility 2.7 M |
Check Kalvista Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kalvista Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 985.3 K, Interest Expense of 0.0 or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 46.33, Dividend Yield of 0.0 or Days Sales Outstanding of 268. Kalvista financial statements analysis is a perfect complement when working with Kalvista Pharmaceuticals Valuation or Volatility modules.
Kalvista | Deferred Long Term Liab |
Latest Kalvista Pharmaceuticals' Deferred Long Term Liab Growth Pattern
Below is the plot of the Deferred Long Term Liab of Kalvista Pharmaceuticals over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Kalvista Pharmaceuticals' Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kalvista Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Deferred Long Term Liab | 10 Years Trend |
|
Deferred Long Term Liab |
| Timeline |
Kalvista Deferred Long Term Liab Regression Statistics
| Arithmetic Mean | 726,536 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 372.02 | |
| Mean Deviation | 1,266,933 | |
| Median | 56,000 | |
| Standard Deviation | 2,702,828 | |
| Sample Variance | 7.3T | |
| Range | 10.9M | |
| R-Value | (0.03) | |
| Mean Square Error | 7.8T | |
| R-Squared | 0.0007 | |
| Significance | 0.92 | |
| Slope | (14,803) | |
| Total Sum of Squares | 109.6T |
Kalvista Deferred Long Term Liab History
About Kalvista Pharmaceuticals Financial Statements
Kalvista Pharmaceuticals investors use historical fundamental indicators, such as Kalvista Pharmaceuticals' Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kalvista Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Deferred Long Term Liabilities | 64.4 K | 61.2 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.